SemaglutidePriceGuide
Semaglutide Price Guide is an educational pricing and comparison resource operated by Premium Health Solutions. Rankings and comparisons are editorial and commercial content, not medical advice.

Outcomes

Semaglutide's effects on blood pressure and lipids

Weight loss tends to drag several cardiometabolic numbers in the right direction.

Reviewed 2026-06-04 Physician-reviewed How we research

Quick Answer

Across trials, semaglutide was associated with modest reductions in blood pressure and improvements in lipid measures such as triglycerides, generally accompanying weight loss. These are favorable cardiometabolic signals, though semaglutide is not a dedicated blood-pressure or cholesterol medication. SELECT later showed reduced cardiovascular events. Compounded semaglutide is not FDA-approved.

Key Facts

  • Modest systolic blood-pressure reductions (a few mmHg on average)
  • Improvements in triglycerides and other lipid measures
  • Changes accompany weight loss; responses vary by person
  • Not a substitute for dedicated BP or lipid medications
  • SELECT showed reduced cardiovascular events (separate from markers)

Blood pressure

Semaglutide trials commonly reported small reductions in systolic blood pressure — on the order of a few mmHg on average — consistent with meaningful weight loss. The effect is modest and variable, and semaglutide is not a substitute for dedicated antihypertensive therapy when that is indicated.

Lipids

Improvements in triglycerides and other lipid measures were reported alongside weight loss. Lipid responses vary between individuals and are best interpreted as part of overall cardiometabolic improvement rather than a targeted lipid treatment.

Why these move together

Excess weight, blood pressure, lipids and glucose are interconnected. Reducing weight and improving insulin sensitivity tends to nudge the whole cluster in a healthier direction — which is why one weight-directed therapy can show benefits across several markers at once.

Markers vs outcomes

Improving markers is encouraging but distinct from proving fewer events — which is exactly what SELECT demonstrated for semaglutide in obesity with cardiovascular disease. Treat marker improvements as supportive context. Compounded semaglutide is not FDA-approved.

Frequently asked questions

Does semaglutide lower blood pressure?

Trials reported modest reductions in systolic blood pressure (a few mmHg on average) accompanying weight loss. It is not a dedicated blood-pressure medication.

Does semaglutide improve cholesterol?

Trials reported favorable changes in lipids such as triglycerides alongside weight loss, though responses vary.

References

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
  2. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
  3. Marso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.

Citations are for educational reference; this article summarizes published research in plain language and is not medical advice.

Bottom Line

Semaglutide modestly improves blood pressure and lipids alongside weight loss, and SELECT showed reduced cardiovascular events. It is not a replacement for dedicated BP or lipid treatment.

Related from the Journal

SELECT trial

Cardiovascular events.

STEP-HFpEF

Heart failure.

STEP 1

Core weight data.

Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”
Compare NexLife plans